Tag
The LUMINARA trial evaluates AZD5462, an oral relaxin receptor agonist, demonstrating safety and promising effects on cardiac remodeling and vascular resistance in chronic heart failure, warranting further large-scale investigation.
Serial nuclear magnetic resonance metabolic profiling reveals distinct lipid and inflammatory markers predictive of adverse outcomes in chronic heart failure, supporting its role in improving risk stratification.
Elevated VCAM-1 levels correlate with worse outcomes in chronic HFrEF, independent of conventional markers; dapagliflozin’s benefits are consistent across VCAM-1 levels, highlighting inflammatory pathways as therapeutic targets.
Remote monitoring of systolic, diastolic, and mean pulmonary artery pressures predicts 2-year all-cause mortality in chronic heart failure across ejection fraction categories, informing personalized management strategies.
